Lung Segmentectomy in Non-Small Cell Lung Cancer Surgery: Comparison
Please note this is a comparison between Version 2 by Rita Xu and Version 1 by Giovanni Mugnaini.

Current guidelines recommend surgery for early-stage non-small cell lung cancer (NSCLC). The standard treatment for patients with cT1N0 NSCLC has been lobectomy with lymph-node dissection, with sublobar resection used only in patients with inadequate cardio-respiratory reserve, with poor performance status, or who are elderly. The results of two randomized controlled trial recently had changed the point of view, giving a new important role to the sublobar resections.

  • segmentectomy
  • lung surgery
  • NSCLC
  • lobectomy

1. Introduction

The well-known prospective randomized multi-institutional trial conducted by Ginsberg and Rubenstein and the Lung Cancer Study Group (LCSG) in 1995 demonstrated that lobectomy and systematic lymph node dissection is the standard treatment for early-stage non-small-cell lung cancer (NSCLC) [1] cT1N0. The results of this study showed that sublobar resections had a local recurrence rate three times higher than that of lobectomy and a 50% higher cancer-related mortality rate.
However, in the last two decades several studies have suggested more and more often that sublobar lung resections (wedge resections, but especially anatomic segmentectomies) could be carried out not only in high-comorbidity patients who cannot tolerate lobectomy [2].
From a technical point of view, sublobar resections include both wedge resection and segmentectomy, and the surgical difficulties differ considerably between the two types: wedge resection is the non-anatomical removal of lung tissue containing the tumor, while segmentectomy involves suturing and section of the arteries, veins, and bronchi associated with the lung segment.
In recent years, the detection of small nodules or ground-glass opacities suggestive of tumor has increased due to CT low-dose screening programs and improved diagnostic modalities, so that indication for sublobar resections became more common and some surgeons began to practice them, even though there were no randomized trials. The turning point came in 2022 and early 2023 with the publication of the results of the two most important randomized controlled trials of recent years in this field, the JCOG0802/WJOG4607L study and the CALBG/Alliance 140503 study (Table 1). Both demonstrated the non-inferiority of sublobar resection on oncological outcomes in terms of overall survival (OS), disease-free survival (DFS), and recurrence rate (RR) [3,4][3][4]. Results of the phase III Alliance trial, recently published, showed a 5-year disease-free survival of 63.6% for patients with NSCLC tumors up to 2 cm who underwent a sublobar resection, compared with 64.3% for those who underwent a lobectomy (HR = 1.01). These data allow uresearchers to state that sublobar resections, and more specifically anatomical segmentectomies, could become the standard of care for patients with peripheral cT1aN0 NSCLC (≤2 cm) without metastases to major hilar and mediastinal lymph nodes. Anatomic sublobar resections could also play an important role in terms of post-operative pulmonary functions [5].
Table 1. Summary of randomized controlled trials (RCTs) comparing sublobar resection vs. lobectomy in non-small cell lung cancer.
WResearchers think that, in the near future, segmentectomy will play an increasingly important role, due also to the several ongoing trials that are examining screening for NSCLC and hence the increased possibility of diagnosis of early-stage NSCLC.

2. Surgical Strategies

Since the first segmental resection for lung cancer described by Jenkis et al. [6], the debate has focused on finding the correct indications for sublobar resections to achieve significant outcomes in terms of oncological radicality and OS. Sublobar resections, including either wedge and anatomical resection, may be indicated in two different scenarios:
-
Patients with several comorbidities and limited functional reserve that contraindicate lobectomy, so as to allow them to be eligible for surgical treatment in early-stage NSCLC while accepting the compromise of a lower long-term survival. This class of patients is also influenced by the surgical technique chosen, with better post-operative recovery with minimally invasive techniques such as video-assisted (VATS) or robot-assisted (RATS) thoracotomy.
-
In the case of early diagnosis, following the criteria indicated below, even for patients without comorbidities.
As also indicated by the 2023 NCCN guidelines for NSCLC [7], sublobar resections should be performed in the following case: a single tumor located in the outer third of the parenchyma, NSCLC suspected, clinical stage IA [8], size less than 2 cm in its largest diameter, C/T ratio < 0.5 evaluated using the lung window at CT scan, no lymphnode metastasis.

2.1. Nodule Localization

A crucial point in assessing the feasibility of sublobar resections, both wedge and anatomical, is the size and location of the lesion, which must be a single peripheral nodule, smaller than 2 cm in its largest diameter (considering both the solid component and the associated GGO component). A peripheral lesion is a nodule whose center is in the outer third of the lung parenchyma. This is so that the resection can be technically executable with adequate oncological margins. This type of resection is therefore not applicable for the centroparenchymal nodules.

2.2. Consolidation/Tumor Ratio

With the increasing use of imaging techniques in diagnostic examinations and the availability of low-dose CT devices, the diagnosis of early-stage lung lesions has increased. Based on radiological findings, evaluated using the lung window at CT scan, lung lesions can be classified as follows: pure ground glass nodules (GGN), part-solid nodules, and pure solid nodules. GGO is a descriptive term for a nonspecific radiologic finding that refers to an area of increased attenuation in the lung without blockage of the underlying pulmonary vessels or bronchial structures, whereas in pure solid nodules these underlying structures are no longer visible. In non-mucinous adenocarcinomas of the lung, these lesions (GGO vs. solid opacities) are associated with a lepidic or invasive pattern. This correlation is not absolute and several studies have been performed to discover predictive elements based on radiological finding [9,10,11,12,13][9][10][11][12][13]. The pathological patterns of growth of sub-solid nodules, including pure and partially solid GGN types and pure solid lesions, are obviously different, leading to different prognoses. As expected, sub-solid nodules with the GGO component have a good prognosis; conversely, pure solid lesions are thought to have high invasiveness with a worse prognosis [10,11][10][11]. The results of the JCOG0201 prospective study [13], which showed a consolidation/tumor ratio (CTR) < 0.5 (5-year relapse-free survival 95.9%) [14] as an evaluation criterion for non-invasive lung adenocarcinoma <2.0 cm with a specificity of 98.7% (95% CI: 93.2–100.0%), appear important in this context and this criterion could be used to radiologically define early adenocarcinoma of the lung. CTR was defined as the ratio of the maximum consolidation diameter (C) divided by the maximum tumor diameter (T), which was determined digitally based on the CT scan findings (using the lung window).

2.3. Oncological Margins

The main criticism of sublobar resection (especially in complex segmentectomies) is the smaller extension and amplitude of the parenchymal margins than in a standard lobectomy [15]. For this reason, nodule size and location are the main criteria to be analyzed. Sublobar resections such as anatomical segmentectomies and wedge resection should achieve parenchymal resection margins ≥ 2 cm or bigger than the size of the nodule [7]. The correct distance between the tumor margin and the resection margin should be closely examined in the pre-operative period by evaluating all CT scans (i.e., axial, sagittal, coronal views) including, if possible, 3D reconstruction [16] and intra-operatively confirmed with a frozen section. When required, surgical margins have to be widened to grant the best oncological outcome.

2.4. Complex and Simple Segmentectomy

A proper evaluation of the segmental anatomy of the lung is essential for planning the procedure. Although each segment has a different shape, they can generally be considered pyramidal, with the apex pointing toward the hilum. In the CT study, the segments can be identified by following the bronchial and vascular branches, flowing up and down the axial sections. Compared with the bronchial tree branches, evaluation of arterial and venous branches may be more complex because of their anatomic variability and the fact that more arteries may spray the same segment, whereas more veins may provide drainage. From a surgical perspective, anatomic segmentectomies are currently divided into simple and complex procedures [17]. Simple segmentectomies include resection of the apical segment of the lower lobe (both right and left), lingual segmentectomy, or left superior segmentectomy. Complex segmentectomies are anatomic sublobar resections that include segments other than those previously mentioned (Table 2). From a technical perspective, even when defined as “simple,” these anatomical structures are not always easy to identify and isolate. Compared to standard lobectomies, they require a longer learning curve. WResearchers could define a complex segmentectomy as the one that requires resection of more than one intersegmental plan (i.e., S2 or the S1–S2 bisegments in the right upper lobe) and, as referenced by many authors, are considered as a challenging resection even for a certified thoracic surgeon, also because the broncovascular structures are located deeper [18]. The complexity of this procedure is demonstrated by higher Prolonged Air Leak (PAL) rates and narrower surgical resection margins. Considering the previous paragraph, the correct location of the nodule is crucial in order to ensure adequate resection margins, especially for complex segmentectomies [19]. [Table 1].
Table 2. Simple and complex segmentectomy.

2.5. Lymphadenectomy

As described previously, sublobar resections can be indicated for selected patients with clinical stage IA NSCLC, so pre-operative examination with CT and PET-CT should exclude nodal involvement. In the event that CT examination shows enlargement of mediastinal lymph nodes or PET-CT examination shows hyperactivity of lymph nodes, endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) or mediastinoscopic biopsy must be performed. Segmental lymph node dissection for intra-operative frozen section examination should be performed according to ESTS guidelines, and, as it was recently shown by the JCOG0802 and CALGB trials, absence of metastases in hilar and mediastinal lymph nodes has to be demonstrated as far as possible [20]. The importance of lymphadenectomy and its extension (considering N1 hilar lymph node stations, or N2 mediastinal nodes) are a subject of discussion since lesions that can be applied to this type of resection must be early-stage, node negative. For lobectomies, adequate lymph node dissection, including both hilar and mediastinal nodes, has been shown to be essential to ensure local disease control and to ensure proper staging [21]. In recent years some studies have tried to define this point for sublobar resections [22]. Handa et al. [23], in their multicenter, propensity-score-matched analysis, compared segmentectomies associated with hilar lymphadenectomy with those associated with mediastinal lymphadenectomy and concluded that a well-performed segmentectomy also requires a mediastinal lymphadenectomy, as this procedure allows the harvest of more lymph nodes and provides a more appropriate pathological staging compared to segmentectomies followed only by hilar lymphadenectomy.

2.6. Vats and Rats Resections

Sublobar resections and minimally invasive surgery are evolving together as they share a common goal, that is, to perform a proper and oncologically correct resection with an influence on patients’ post-operative quality of life that is as small as possible. Uniportal VATS resections are now performed all around the world with a standardized technique, although the learning curve is a little longer than that of standard VATS resections. In addition, robot-assisted resections are performed worldwide. RATS segmentectomies have similar post-operative outcomes compared to VATS resections in terms of post-operative complications, quality of life, and pain management, without any difference in oncological outcomes or number of lymph node stations resected. Furthermore, in RATS, the better visualization of the hilar structures of the lung segment often allows a more anatomically correct resection to be performed [24].

References

  1. Ginsberg, R.J.; Rubinstein, L.V. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann. Thorac. Surg. 1995, 60, 615–623.
  2. Winckelmans, T.; Decaluwé, H.; De Leyn, P.; Van Raemdonck, D. Segmentectomy or lobectomy for early-stage non-small-cell lung cancer: A systematic review and meta-analysis. Eur. J. Cardiothorac. Surg. 2020, 57, 1051–1060.
  3. Saji, H.; Okada, M.; Tsuboi, M.; Nakajima, R.; Suzuki, K.; Aokage, K.; Aoki, T.; Okami, J.; Yoshino, I.; Ito, H.; et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022, 399, 1607–1617.
  4. Altorki, N.; Wang, X.; Kozono, D.; Watt, C.; Landrenau, R.; Wigle, D.; Port, J.; Jones, D.R.; Conti, M.; Ashrafi, A.S.; et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2023, 388, 489–498.
  5. Bongiolatti, S.; Salvicchi, A.; Mugnaini, G.; Vokrri, E.; Viggiano, D.; Gonfiotti, A.; Lavorini, F.; Voltolini, L. Does thoracoscopic basal pyramid segmentectomy really offer functional advantages in comparison with thoracoscopic lower lobectomy? Interdiscip. Cardiovasc. Thorac. Surg. 2023, 36, ivad018.
  6. Jensik, R.J.; Faber, L.P.; Milloy, F.J.; Monson, D.O. Segmental resection for lung cancer. A fifteen-year experience. J. Thorac. Cardiovasc. Surg. 1973, 66, 563–572.
  7. NCCN Guidelines, Version 2.2023-Non Small Cell Lung Cancer. Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 (accessed on 13 April 2023).
  8. Goldstraw, P.; Chansky, K.; Crowley, J.; Rami-Porta, R.; Asamura, H.; Eberhardt, W.E.; Nicholson, A.G.; Groome, P.; Mitchell, A.; Bolejack, V.; et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J. Thora. Oncol. 2016, 11, 39–51.
  9. Handa, Y.; Tsutani, Y.; Okada, M. Transition of Treatment for Ground Glass Opacity-Dominant Non-Small Cell Lung Cancer. Front. Oncol. 2021, 11, 655651.
  10. Travis, W.D.; Asamura, H.; Bankier, A.A.; Beasley, M.B.; Detterbeck, F.; Flieder, D.B.; Goo, J.M.; MacMahon, H.; Naidich, D.; Nicholson, A.G.; et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J. Thorac. Oncol. 2016, 11, 1204–1223.
  11. Sun, K.; You, A.; Wang, B.; Song, N.; Wan, Z.; Wu, F.; Zhao, W.; Zhou, F.; Li, W. Clinical T1aN0M0 lung cancer: Differences in clinicopathological patterns and oncological outcomes based on the findings on high-resolution computed tomography. Eur. Radiol. 2021, 31, 7353–7362.
  12. Takahashi, M.; Shigematsu, Y.; Ohta, M.; Tokumasu, H.; Matsukura, T.; Hirai, T. Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters. J. Thorac. Cardiovasc. Surg. 2014, 147, 54–59.
  13. Suzuki, K.; Koike, T.; Asakawa, T.; Kusumoto, M.; Asamura, H.; Nagai, K.; Tada, H.; Mitsudomi, T.; Tsuboi, M.; Shibata, T.; et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J. Thorac. Oncol. 2011, 6, 751–756.
  14. Asamura, H.; Hishida, T.; Suzuki, K.; Koike, T.; Nakamura, K.; Kusumoto, M.; Nagai, K.; Tada, H.; Mitsudomi, T.; Tsuboi, M.; et al. Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201. J. Thorac. Cardiovasc. Surg. 2013, 146, 24–30.
  15. Nitadori, J.-I.; Bograd, A.J.; Morales, E.A.; Rizk, N.P.; Dunphy, M.P.S.; Sima, C.S.; Rusch, V.W.; Adusumilli, P.S. Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2 cm. Ann. Surg. Oncol. 2013, 20, 4282–4288.
  16. Hattori, A.; Matsunaga, T.; Fukui, M.; Takamochi, K.; Oh, S.; Suzuki, K. Oncologic outcomes of segmentectomy for stage IA radiological solid-predominant lung cancer >2 cm in maximum tumour size. Interact. Cardiovasc. Thorac. Surg. 2022, 35, ivac246.
  17. Handa, Y.; Tsutani, Y.; Mimae, T.; Tasaki, T.; Miyata, Y.; Okada, M. Surgical Outcomes of Complex Versus Simple Segmentectomy for Stage I Non-Small Cell Lung Cancer. Ann. Thorac. Surg. 2019, 107, 1032–1039.
  18. Bongiolatti, S.; Salvicchi, A.; Indino, R.; Vokrri, E.; Gonfiotti, A.; Borgianni, S.; Viggiano, D.; Voltolini, L. Post-operative and early oncological results of simple and complex full thoracoscopic segmentectomies for non-small-cell lung cancer. Asian Cardiovasc. Thorac. Ann. 2023, 31, 123–132.
  19. Petersen, R.H. Is complex segmentectomy safe? Eur. J. Cardiothorac. Surg. 2021, 61, 108–109.
  20. De Leyn, P.; Dooms, C.; Kuzdzal, J.; Lardinois, D.; Passlick, B.; Rami-Porta, R.; Turna, A.; Van Schil, P.; Venuta, F.; Waller, D.; et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 2014, 45, 787–798.
  21. Lardinois, D.; De Leyn, P.; Van Schil, P.; Porta, R.R.; Waller, D.; Passlick, B.; Zielinski, M.; Lerut, T.; Weder, W. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 2006, 30, 787–792.
  22. Huang, Q.; Wang, R.; Gu, C.; Pan, C.; Zhao, H.; Luo, Q.; Wang, Y.; Zheng, J.; Chen, H. Appropriate lymphadenectomy significantly reduced recurrence after segmentectomy for patients with non-small cell lung cancer. J. Thorac. Dis. 2018, 10, 1919–1926.
  23. Handa, Y.; Tsutani, Y.; Mimae, T.; Miyata, Y.; Ito, H.; Nakayama, H.; Ikeda, N.; Okada, M. Appropriate Extent of Lymphadenectomy in Segmentectomy: A Multicenter Study. Jpn J. Clin. Oncol. 2021, 51, 451–458.
  24. Zhang, J.; Feng, Q.; Huang, Y.; Ouyang, L.; Luo, F. Updated Evaluation of Robotic- and Video-Assisted Thoracoscopic Lobectomy or Segmentectomy for Lung Cancer: A Systematic Review and Meta-Analysis. Front. Oncol. 2022, 12, 853530.
More
Video Production Service